The agency says the measure will ensure financial advisers act in retirement savers’ best interests
Big moves stir speculation the company may be revising the allocations of its model portfolios
The central bank bought bonds issued by AT&T, UnitedHealth and Walmart
Short interest as a portion of shares outstanding in the $266 billion SPDR S&P 500 ETF had fallen to 4.9% Friday from 6.7% at the end of May
The asset manager is reducing the cost of key iShare funds by one basis point
For the first time, individual investors will have direct access to coveted DFA strategies
After the tragic death of a customer, the investment platform made significant changes. More may need to be done
Only 0.1% of plan assets are in ESG-specific funds, but many, if not most, investment products have integrated ESG criteria
Sandlapper Securities may have some fight left, says CEO Trevor Gordon
Credit Suisse’s decision to delist nine exchange-traded notes worth nearly $3 billion points to an existential crisis in this sector of the ETF market
Participants in the $557 billion Thrift Savings Plan will have many more target-date vintages available to them starting in July
The product includes five glide paths and can include investment options that are already on plan menus
Threats to the equity rally include a COVID second wave, U.S.-China tensions and the prospect that central banks will wind down their stimulus efforts
Bank is axing a total of nine ETNs, most of which are leveraged
A bipartisan bill to amend the Internal Revenue Code hints at more attention to the issue, according to a report from Morningstar
There's more to the so-called free trades than meets the eye
U.S. regulators dropped the ball in a recent letter clarifying that regulations do not prohibit the use of private equity funds in 401(k) plans
Massive stimulus efforts may not be enough to overcome the challenges posed by high unemployment, damage to small businesses
The architect of the DOL fiduciary rule remains skeptical of the SEC measure
The fund's biggest holding is Moderna, whose stock price has more than tripled this year on news about vaccine it's developing
